Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:CING NASDAQ:MGNX NASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$0.90+3.0%$1.21$0.82▼$4.08$234.16M0.264.98 million shs16.69 million shsCINGCingulate$5.09+4.1%$5.06$3.16▼$11.89$65.86M-0.85850,473 shs293,665 shsMGNXMacroGenics$4.01+3.6%$3.65$1.18▼$4.64$245.99M1.18937,634 shs712,658 shsTRDAEntrada Therapeutics$6.31+5.7%$9.98$4.93▼$16.45$231.76M-0.26328,381 shs339,822 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics-5.12%-9.98%-24.10%-37.65%-77.73%CINGCingulate+5.16%+0.20%-1.41%-46.38%-1.21%MGNXMacroGenics-1.02%-7.86%+31.19%+24.04%+117.42%TRDAEntrada Therapeutics-6.28%-9.27%-14.71%-54.01%-27.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$0.90+3.0%$1.21$0.82▼$4.08$234.16M0.264.98 million shs16.69 million shsCINGCingulate$5.09+4.1%$5.06$3.16▼$11.89$65.86M-0.85850,473 shs293,665 shsMGNXMacroGenics$4.01+3.6%$3.65$1.18▼$4.64$245.99M1.18937,634 shs712,658 shsTRDAEntrada Therapeutics$6.31+5.7%$9.98$4.93▼$16.45$231.76M-0.26328,381 shs339,822 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics-5.12%-9.98%-24.10%-37.65%-77.73%CINGCingulate+5.16%+0.20%-1.41%-46.38%-1.21%MGNXMacroGenics-1.02%-7.86%+31.19%+24.04%+117.42%TRDAEntrada Therapeutics-6.28%-9.27%-14.71%-54.01%-27.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 2.20Hold$4.67418.86% UpsideCINGCingulate 2.50Moderate Buy$27.33437.00% UpsideMGNXMacroGenics 2.29Hold$5.5037.16% UpsideTRDAEntrada Therapeutics 2.33Hold$17.50177.34% UpsideCurrent Analyst Ratings BreakdownLatest CING, MGNX, AKBA, and TRDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026TRDAEntrada Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $17.006/8/2026CINGCingulate Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$55.00 ➝ $52.005/26/2026CINGCingulate HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.005/22/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026CINGCingulate Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/8/2026MGNXMacroGenics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026TRDAEntrada Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.005/8/2026TRDAEntrada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/6/2026AKBAAkebia Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/6/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/20/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$236.20M1.02N/AN/A$0.12 per share7.50CINGCingulateN/AN/AN/AN/A$0.31 per shareN/AMGNXMacroGenics$149.50M1.70N/AN/A$0.88 per share4.56TRDAEntrada Therapeutics$25.42M9.64N/AN/A$8.01 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)CINGCingulate-$22.45M-$4.23N/AN/AN/AN/A-365.15%-158.55%8/18/2026 (Estimated)MGNXMacroGenics-$74.62M-$1.10N/AN/AN/A-44.79%-147.80%-28.40%8/13/2026 (Estimated)TRDAEntrada Therapeutics-$143.75M-$3.99N/AN/AN/A-2,895.05%-51.22%-42.20%8/5/2026 (Estimated)Latest CING, MGNX, AKBA, and TRDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CINGCingulate-$0.53-$0.95-$0.42-$0.95N/AN/A5/13/2026Q1 2026MGNXMacroGenics-$0.57-$0.58-$0.01-$0.58$15.24 million$20.78 million5/7/2026Q1 2026AKBAAkebia Therapeutics-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 million5/7/2026Q1 2026TRDAEntrada Therapeutics-$1.06-$0.95+$0.11-$0.95$2.92 million$0.88 million3/18/2026Q4 2025CINGCingulate-$0.56-$0.84-$0.28-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.331.401.33CINGCingulateN/A2.552.55MGNXMacroGenicsN/A1.901.80TRDAEntrada TherapeuticsN/A13.9013.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CINGCingulate41.31%MGNXMacroGenics96.89%TRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics4.30%CINGCingulate5.30%MGNXMacroGenics13.60%TRDAEntrada Therapeutics9.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430268.26 million256.72 millionOptionableCINGCingulate2013.47 million12.76 millionNot OptionableMGNXMacroGenics43063.56 million54.92 millionOptionableTRDAEntrada Therapeutics11038.82 million35.14 millionOptionableCING, MGNX, AKBA, and TRDA HeadlinesRecent News About These CompaniesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)June 9 at 9:31 AM | theglobeandmail.comEntrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8 at 12:01 PM | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAJune 4, 2026 | prnewswire.comIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 StudyJune 2, 2026 | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAJune 2, 2026 | globenewswire.comIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 StudyJune 2, 2026 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | markets.businessinsider.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 28, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 26, 2026 | globenewswire.comBernhardt Zeiher Buys 5,000 Shares of Entrada Therapeutics (NASDAQ:TRDA) StockMay 22, 2026 | insidertrades.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 21, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 19, 2026 | globenewswire.comINVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLCMay 18, 2026 | globenewswire.comTRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the ...May 18, 2026 | caledonianrecord.comCTRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law FirmMay 17, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 14, 2026 | prnewswire.comHC Wainwright Has Positive Estimate for TRDA Q2 EarningsMay 12, 2026 | marketbeat.comEntrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 11, 2026 | globenewswire.comHC Wainwright & Co. downgrades Entrada Therapeutics (TRDA)May 9, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Beam Therapeutics (BEAM)May 9, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMicron’s $1 Trillion Memory Melt-UpBy Jeffrey Neal Johnson | May 27, 2026IREN's 800MW Bet Flips the AI Power SwitchBy Jeffrey Neal Johnson | June 6, 2026Vertical Aerospace: Pre-Flight Checks Point to a BreakoutBy Jeffrey Neal Johnson | May 20, 2026RTX Is Set to Revolutionize Munitions ManufacturingBy Jeffrey Neal Johnson | May 28, 2026The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearBy Chris Markoch | May 25, 2026CING, MGNX, AKBA, and TRDA Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$0.90 +0.03 (+3.04%) Closing price 04:00 PM EasternExtended Trading$0.89 -0.01 (-0.93%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Cingulate NASDAQ:CING$5.09 +0.20 (+4.09%) Closing price 04:00 PM EasternExtended Trading$5.05 -0.04 (-0.79%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.MacroGenics NASDAQ:MGNX$4.01 +0.14 (+3.62%) Closing price 04:00 PM EasternExtended Trading$4.00 0.00 (-0.12%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Entrada Therapeutics NASDAQ:TRDA$6.31 +0.34 (+5.70%) Closing price 04:00 PM EasternExtended Trading$6.30 -0.01 (-0.16%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore SpaceX IPO Fears Are Overblown, But the AI Bet Is Real The Biggest Opportunity From SpaceX’s IPO May Surprise You NVIDIA’s Outlook Gains Momentum: Stock Price to Follow Chewy’s Growth Engine Is Stronger Than the Market Thinks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
